Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery

Published
30 Dec 24
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
SEK 815.43
21.0% undervalued intrinsic discount
08 Aug
SEK 644.50
Loading
1Y
-5.2%
7D
-1.3%

Author's Valuation

SEK 815.4

21.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 0.10%

Shared on23 Apr 25
Fair value Increased 2.43%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 2.38%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 9.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 4.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 4.52%

AnalystConsensusTarget has increased profit margin from 32.7% to 48.9%, decreased future PE multiple from 29.2x to 17.9x and decreased shares outstanding growth rate from 0.0% to 0.0%.

Shared on12 Mar 25
Fair value Decreased 4.80%

AnalystConsensusTarget has decreased profit margin from 66.1% to 32.7% and increased future PE multiple from 14.4x to 29.2x.